ArticleFASEB bioAdvances2021
Human-specific polymorphic pseudogenization of
Article in FASEB bioAdvances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- Siglecs: From Biomodulation to Immunotherapy.Current protein & peptide science · 2026Review
- Decoding SIGLEC12 in Bladder Cancer: In Silico Profiling of Expression, Tumor-Immune Interactions, and Prognostic Impact.Medicina (Kaunas, Lithuania) · 2025Article
- Tumor-expressed GPNMB orchestrates Siglec-9Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Role of Glycans in Human Immunity-A Sweet Code.Molecules (Basel, Switzerland) · 2025Review
- Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers.JCI insight · 2024Article
- Analysis ofHeliyon · 2024Article
- Comparative physiological anthropogeny: exploring molecular underpinnings of distinctly human phenotypes.Physiological reviews · 2023Review
- Review
- Gangliosides as Siglec ligands.Glycoconjugate journal · 2023Review
- Discovery, classification, evolution and diversity of Siglecs.Molecular aspects of medicine · 2023Review
- Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.Journal of translational medicine · 2022Article
- Siglecs as Therapeutic Targets in Cancer.Biology · 2021Review
- Siglec Ligands.Cells · 2021Review
- Broadening the spectrum of cancer genes under selection in human populations.FASEB bioAdvances · 2021Article
- Ongoing selection for a uniquely human null allele ofFASEB bioAdvances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
Compared with our closest living evolutionary cousins, humans appear unusually prone to develop carcinomas (cancers arising from epithelia). The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.